Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs RXRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PVLA Captures Overall Composite Edge (48.2 HOLD vs 49.5 HOLD), While RXRX Leads 5–1 on Growth & Valuation Pillars

PVLA Overall Winner 6-Pillar Tally: PVLA 1 – 5 RXRX Matrix Metrics: PVLA 4 – 3 RXRX

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Recursion Pharmaceuticals, Inc. (RXRX) on higher Unified Composite conviction (48.2/100 HOLD vs. 49.5/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality), while RXRX wins 5–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus RXRX at $2.90 (N/M Forward P/E, -734.2% operating margin).

  • Composite vs. Pillar Nuance: While RXRX currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -734.2% operating margin) and revenue trajectory (+0.0% vs. +258.5% YoY).
  • Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile RXRX is in a Breakdown options structure phase (RSI 35.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs RXRX
PVLA NASDAQ Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
RXRX NASDAQ
Recursion Pharmaceuticals, Inc. Class A Common Stock
Biological Products, (No Disgnostic Substances)
$2.90
-8.79% 1D
Market Cap $2.1B
TTM Revenue $68M
Forward P/E N/M
Beta / 30D Vol 3.01β · 85% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.7 · SMA20: $3.69 · SMA50: $3.77

6-Pillar Scorecard Institutional Category Breakdown (PVLA 1 – 5 RXRX)

Columns: Metric · PVLA · RXRX
1. Valuation Multiples RXRX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 23.5x
2. Growth & Scale RXRX
Revenue Growth (YoY) +0.0% +258.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $68M
Market Cap $2.2B $2.1B
3. Profitability & Quality PVLA
Gross Margin N/A N/A
Operating Margin 0.0% -734.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -63.4% -48.7%
4. Balance Sheet & Cash Flow RXRX
Cash Generation (TTM) -$43M -$314M
Cash Flow Margin N/A N/A
Net Cash / Leverage $193M Net Cash $475M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RXRX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 47.9% (2nd %ile) 92.3% (61st %ile)
Put/Call OI Skew 3.82x (Put-Skewed) 0.58x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat RXRX
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (4) vs RXRX (3)
Institutional Metric PVLA RXRX Criterion Row Edge
Market Capitalization
Scale
$2.2B $2.1B Larger Scale PVLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +258.5% Higher Growth RXRX
Operating Margin (TTM)
Profitability
0.0% -734.2% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-63.4% -48.7% Higher ROE RXRX
52-Week Range Position
Momentum
68% ($72–$180) 6% ($3–$5) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 3.01β · 85% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 49.5 / 100 (HOLD) Higher Composite RXRX
Trailing 12M Revenue (USD)
Operating Scale
N/A $68M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 23.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$314M ($475M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +36.72 pp
PVLA: +20.56% · RXRX: -16.16%
3M Horizon PVLA +2.41 pp
PVLA: -3.58% · RXRX: -5.99%
6M Horizon PVLA +37.54 pp
PVLA: +38.06% · RXRX: +0.52%
1Y Horizon PVLA +113.07 pp
PVLA: +80.16% · RXRX: -32.91%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PVLA Revenue RXRX Revenue PVLA Op. Margin RXRX Op. Margin Margin Leader
FY2018 $30M N/A -113.1% N/A PVLA
FY2019 $40M $0M -62.2% -2692.6% PVLA
FY2020 $30M $0M -115.7% -2135.7% PVLA
FY2021 $30M $10M -165.0% -1795.8% PVLA
FY2022 $30M $40M -167.8% -616.7% PVLA
FY2023 $40M $40M -27.7% -785.3% PVLA
FY2024 N/A $60M N/A -814.1% RXRX
FY2025 N/A $70M N/A -867.9% RXRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RXRX BREAKDOWN
30d in phase · OBV DISTRIBUTION
Current IV 92.3%
IV Percentile 61st %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact RXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RXRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -734.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · AI Drug Discovery

Investor FAQ PVLA vs RXRX Key Questions & Quantitative Answers

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Recursion Pharmaceuticals, Inc. (RXRX) on higher Unified Composite conviction (48.2/100 HOLD vs. 49.5/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality), while RXRX wins 5–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus RXRX at $2.90 (N/M Forward P/E, -734.2% operating margin). Composite vs. Pillar Nuance: While RXRX currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -734.2% operating margin) and revenue trajectory (+0.0% vs. +258.5% YoY). Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile RXRX is in a Breakdown options structure phase (RSI 35.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RXRX leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RXRX at +258.5% YoY revenue growth and +0.0% YoY earnings growth on $68M TTM revenue (N/A gross margin, -734.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PVLA cumulative revenue shifted +33.3% while RXRX shifted +600.0%. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RXRX.

RXRX screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 23.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus RXRX (-48.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, RXRX carries 92.3% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.